Jpmorgan Chase & CO Myriad Genetics Inc Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Myriad Genetics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 425,244 shares of MYGN stock, worth $4.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
425,244
Previous 566,130 24.89%
Holding current value
$4.56 Million
Previous $15.5 Million 62.37%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$13.17 - $27.03 $1.86 Million - $3.81 Million
-140,886 Reduced 24.89%
425,244 $5.83 Million
Q3 2024

Dec 26, 2024
SELL
$23.97 - $28.6 $181,956 - $217,102
-7,591 Reduced 1.32%
566,130 $15.5 Million
Q3 2024

Nov 08, 2024
SELL
$23.97 - $28.6 $181,956 - $217,102
-7,591 Reduced 1.32%
566,130 $15.5 Million
Q2 2024

Dec 26, 2024
BUY
$17.98 - $25.47 $136,486 - $193,342
7,591 Added 1.34%
573,721 $14 Million
Q2 2024

Aug 12, 2024
BUY
$17.98 - $25.47 $8.43 Million - $11.9 Million
468,847 Added 447.06%
573,721 $14 Million
Q1 2024

Dec 26, 2024
SELL
$17.59 - $23.59 $8.11 Million - $10.9 Million
-461,256 Reduced 81.48%
104,874 $2.24 Million
Q1 2024

May 10, 2024
SELL
$17.59 - $23.59 $756,827 - $1.01 Million
-43,026 Reduced 29.09%
104,874 $2.24 Million
Q4 2023

Dec 26, 2024
SELL
$13.91 - $21.32 $5.82 Million - $8.92 Million
-418,230 Reduced 73.88%
147,900 $2.83 Million
Q4 2023

Feb 12, 2024
BUY
$13.91 - $21.32 $191,026 - $292,787
13,733 Added 10.24%
147,900 $2.83 Million
Q3 2023

Nov 14, 2023
BUY
$15.99 - $23.22 $7,819 - $11,354
489 Added 0.37%
134,167 $2.15 Million
Q2 2023

Aug 11, 2023
SELL
$17.56 - $23.76 $424,671 - $574,611
-24,184 Reduced 15.32%
133,678 $3.1 Million
Q1 2023

May 18, 2023
BUY
$15.26 - $23.75 $1.54 Million - $2.39 Million
100,609 Added 175.73%
157,862 $3.67 Million
Q1 2023

May 11, 2023
SELL
$15.26 - $23.75 $1.27 Million - $1.98 Million
-83,433 Reduced 59.3%
57,253 $1.33 Million
Q4 2022

Feb 13, 2023
SELL
$14.51 - $20.99 $311,486 - $450,592
-21,467 Reduced 13.24%
140,686 $2.04 Million
Q3 2022

Nov 14, 2022
SELL
$18.21 - $27.88 $2.49 Million - $3.82 Million
-136,900 Reduced 45.78%
162,153 $3.09 Million
Q2 2022

Aug 11, 2022
SELL
$16.45 - $25.88 $8.08 Million - $12.7 Million
-490,990 Reduced 62.15%
299,053 $5.44 Million
Q1 2022

May 11, 2022
BUY
$22.67 - $28.01 $1.76 Million - $2.17 Million
77,552 Added 10.88%
790,043 $19.9 Million
Q4 2021

Feb 10, 2022
SELL
$24.13 - $32.63 $850,268 - $1.15 Million
-35,237 Reduced 4.71%
712,491 $19.7 Million
Q3 2021

Nov 12, 2021
BUY
$29.97 - $36.66 $22.4 Million - $27.4 Million
747,728 New
747,728 $24.1 Million

Others Institutions Holding MYGN

# of Institutions
228
Shares Held
92M
Call Options Held
297K
Put Options Held
20.7K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $865M
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email